Literature DB >> 31935066

Therapeutic Contact Lens for Scavenging Excessive Reactive Oxygen Species on the Ocular Surface.

Seung Woo Choi1, Bong Geun Cha2, Jaeyun Kim1,2,3,4.   

Abstract

Excessive reactive oxygen species (ROS) play a significant role in the pathogenesis of many eye diseases. Controlling oxidative stress by reducing the amount of ROS is a potential therapeutic strategy for the prevention and treatment of eye diseases, particularly ocular surface diseases. Ceria nanoparticles (CeNPs) have been investigated owing to their efficient ROS-scavenging properties. To overcome the disadvantages of eyedrop administration due to rapid elimination on the surface of the eye and to retain the intrinsic properties of contact lenses, we developed an ROS-scavenging water-soluble CeNP-embedded contact lens (CeNP-CL) for the prevention of ocular surface diseases. The intrinsic ROS-scavenging property of the CeNPs, which mimicked the activities of superoxide dismutase and catalase, was incorporated into polyhydroxyethyl methacrylate-based contact lenses. The CeNP-CL exhibited high transparency and physical properties comparable to those of a commercial contact lens, along with excellent extracellular ROS-scavenging properties. The viabilities of human conjunctival epithelial cells and human meibomian gland epithelial cells were significantly enhanced in the presence of CeNP-CLs, even in media with high H2O2 contents (100 and 500 μM). Additionally, the wearing of CeNP-CLs on the eyes had a protective effect in a mouse model when 3% H2O2 eyedrops were administered. These results indicate the salvaging effect of the CeNP-CL in a high-ROS environment on the ocular surface, which may be helpful for the treatment of ocular surface diseases.

Entities:  

Keywords:  cerium oxide nanoparticles; dry eye syndrome; meibomian gland dysfunction; ocular surface diseases; reactive oxygen species; therapeutic contact lenses

Mesh:

Substances:

Year:  2020        PMID: 31935066     DOI: 10.1021/acsnano.9b10145

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  6 in total

1.  Ultrasmall Antioxidant Cerium Oxide Nanoparticles for Regulation of Acute Inflammation.

Authors:  Johoon Kim; Gwanui Hong; Luda Mazaleuskaya; Jessica C Hsu; Derick N Rosario-Berrios; Tilo Grosser; Park F Cho-Park; David P Cormode
Journal:  ACS Appl Mater Interfaces       Date:  2021-12-16       Impact factor: 9.229

Review 2.  Lab-on-a-Contact Lens: Recent Advances and Future Opportunities in Diagnostics and Therapeutics.

Authors:  Yangzhi Zhu; Shaopei Li; Jinghang Li; Natashya Falcone; Qingyu Cui; Shilp Shah; Martin C Hartel; Ning Yu; Patric Young; Natan Roberto de Barros; Zhuohong Wu; Reihaneh Haghniaz; Menekse Ermis; Canran Wang; Heemin Kang; Junmin Lee; Solmaz Karamikamkar; Samad Ahadian; Vadim Jucaud; Mehmet R Dokmeci; Han-Jun Kim; Ali Khademhosseini
Journal:  Adv Mater       Date:  2022-04-11       Impact factor: 32.086

Review 3.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

Review 4.  Cerium Oxide Nanoparticles (Nanoceria): Hopes in Soft Tissue Engineering.

Authors:  Hossein Sadidi; Sara Hooshmand; Ali Ahmadabadi; Seyed Javad Hosseini; Francesco Baino; Morvarid Vatanpour; Saeid Kargozar
Journal:  Molecules       Date:  2020-10-06       Impact factor: 4.411

5.  Smart Contact Lens with Dual-Sensing Platform for Monitoring Intraocular Pressure and Matrix Metalloproteinase-9.

Authors:  Ying Ye; Yuancai Ge; Qingwen Zhang; Meiling Yuan; Yu Cai; Kang Li; Yang Li; Ruifeng Xie; Changshun Xu; Danfeng Jiang; Jia Qu; Xiaohu Liu; Yi Wang
Journal:  Adv Sci (Weinh)       Date:  2022-02-23       Impact factor: 17.521

Review 6.  Ocular Nanomedicine.

Authors:  Zhimin Tang; Xianqun Fan; Yu Chen; Ping Gu
Journal:  Adv Sci (Weinh)       Date:  2022-02-12       Impact factor: 17.521

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.